(AOF) – Gilead announced Thursday the suspension of registrations to test its anticancer drug, magrolimab, on solid tumors. This decision comes a week after the American regulator suspended certain studies due to an increased risk of patient death. According to Reuters, Gilead is currently reviewing the benefit/risk balance of magrolimab in all ongoing trials and will provide a review of this assessment as soon as possible.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
